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Poly(amidoamine) and Poly(propylenimine) dendrimers with different generations
and peripheral groups were studied as solubility enhancers and nanocarriers for
7-bromo-2-hydroxy-phenazine N5,N10-dioxide. This compound possesses
potential antitumoral and anti-trypanosomal activity, but its low solubility in
physiological media precludes its possible application as therapeutic drug. The
amino terminated dendrimers association with the active compounds as observed.e01528
vier Ltd. This is an open access article under the CC BY-NC-ND license
y-nc-nd/4.0/).
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Article Nowe01528trough NMR studies showed that electrostatic interactions are essential in the
solubilization enhancement process. The obtaining of a stable and no cytotoxic
formulation makes the drug-carried association a suitable strategy for the
generation of a drug delivery system for phenazine derivatives.
Keywords: Organic chemistry, Physical chemistry, Pharmaceutical chemistry
1. Introduction
Cancer is the second worldwide leading cause of death [1]. Cancer cases are
increasing due to growth and the aging of the population, as well as a growing
prevalence of risk factors such as smoking, overweight and sedentary lifestyle
[2]. In the last decades, scientific and economic efforts around this issue have
been successful in the reduction of the overall rate of deaths originated by cancer,
as well as in the increase in the survival years [3]. However, the World Health Or-
ganization (WHO) estimates that cancer death will continue to rise worldwide to
reach 13.1 million by 2030 [4]. These trends show that although progresses are
being made against the disease, much work remains to be done. One of the chal-
lenges is focused on the optimization of chemotherapies carried out with conven-
tional drugs, which involves the creation of even more effective treatments with
fewer side effects [5]. In this sense, the use of nanocarriers for diagnosis or treat-
ment has allowed to improve the aqueous solubility of active compounds, and
consequently its bioavailability [6]. Also, this strategy can increase the local con-
centration of the drug in the tumoral area, due to the enhanced of permeability and
retention (EPR) effect [7, 8]. Furthermore, the use of nanostructured host-guest
systems for antitumor drug delivery facilitates the drug localization in the site
to be treated, often through pathways based in specific interaction between a
ligand located in the carrier and some cellular receptor [9, 10]. The drug concen-
tration increment in the affected area (and the consequent diminution in systemic
concentration), increases the treatment efficiency and reduces adverse collateral
effects [11, 12].
The research and development of new materials for drug delivery includes the
application, of nanoparticles, liposomes, polymers, hydrogels and dendrimers,
among others [5, 13, 14, 15]. In particular the dendrimers have been exten-
sively studied for this purpose [16, 17, 18]. These macromolecules belonging
to the polymer family have a well-defined and highly branched structure, with
very low polydispersity [19]. This last characteristic differentiate dendrimers
from other polymers, making these materials of great utility in medicinal
uses, because they monodispersity results in a high pharmacokinetic and phar-
macodynamic reproducibility [20, 21]. Poly(amidoamine) and Poly(propyleni-
mine) (PAMAM and PPI respectively) are the most studied dendrimers inon.2019.e01528
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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aqueous solubility and biocompatibility, low immunogenicity, and the pres-
ence of modifiable peripheral functional groups [23, 24]. The high density
of terminal groups and internal cavities in the PAMAM and PPI dendrimers
promotes drug association, resulting in the improvement of aqueous solubility
of lipophilic therapeutic compounds [25] such as candersatan cilexetil [26],
hydrochlorothiazide [27], crocetin [28] and doxorubicin [29]. Also, several
ionic drugs such as mycophenolic acid [30], daidzein [31] phenobarbital
and zulfamethoxazole [32] have been associate to dendrimeric carriers.
On the other hand, a class of compounds that have been tested as anticancer
agents are phenazines [33, 34, 35], in particular N,N0-phenazine dioxide deriv-
atives [36]. The studies carried out to date have shown that these last com-
pounds are selective cytotoxic agents under hypoxia condition, a particular
characteristic that is present in solid tumors [37]. These compounds combine
two bioactive chemical clusters: a bioreducible system, the N-oxide function,
and a flat structure, phenazine, which can interact with DNA [38]. One of this
antitumoral derivatives is 7-bromo-2-hydroxy-phenazine N5,N10-dioxide (Phen-
azine, Fig. 1). This compound exhibited in vitro antitumoral activity and high
selectivity for hypoxia conditions [39]. However, the low water solubility de-
creases its bioavailability and effectiveness for successful in vivo usage [27].
Thus, the incorporation of this active compound to a water soluble dendri-
meric carrier would allow the development of clinical formulations. Up to
the present we have achieved, using various dendrimeric systems, the associ-
ation and release of different hydrophobic compounds with biological activity
[40, 41, 42, 43, 44]. In this work, we studied the association of the anionic
Phenazine drug with four low generation dendrimers (PAMAM and PPI types,
Fig. 2) with the aim of enhancing its aqueous solubility. It has been reported
[45, 56] that generations smaller than 5 of PAMAM dendrimers do not pre-
sent significant in vivo toxicity, suggesting that formulations involving this
carriers appear to have little or no deleterious effects in biological applica-
tions. Nevertheless, the cytotoxicity of the formulation in normal Madin
Darby Canine Kidney cells (MDCK) was evaluated.Fig. 1. Molecular structure of 7-bromo-2-hydroxy-phenazine N5, N10-dioxide (Phenazine).
on.2019.e01528
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 2. Chemical structure of PAMAM-AT (G ¼ 1), PAMAM-AT (G ¼ 3), PAMAM-OHT (G ¼ 3) and
PPI (G ¼ 4).
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2.1. Materials
Generation 1 and 3 ethylenediamine cored and amine terminated PAMAM den-
drimers (PAMAM-AT (G¼ 1), PAMAM-AT (G¼ 3)), and generation 3 ethylenedi-
amine cored and hydroxy terminated PAMAM dendrimer (PAMAM-OHT (G¼ 3)),
were obtained from Sigma-Aldrich (solutions 20 wt.% in methanol). Generation 4
diamine butane cored and amine terminated PPI dendrimer (PPI (G ¼ 4)) was ob-
tained from Sigma-Aldrich. 7-bromo-2-hydroxy-phenazine N5,N10-dioxide (Phena-
zine) was synthesized as previously described [33] and stored at room temperature
under vacuum. The pKa of Phenazine was determined by spectrophotometric titra-
tion [46, 47]. Methanol was purchased from Sintorgan in HPLC quality and deion-
ized water was obtained from Elga Classic equipment (resistivity of 18 MU cm).
Phosphate-buffered saline solution (PBS pH ¼ 7.4) was prepared (150 mM NaCl;
1.9 mM NaH2PO4; 8.1 mM Na2HPO4). All the chemicals were used as received
without further purification.2.2. Formation of phenazine/dendrimer conjugates
Appropriate aliquots of stock solution of PPI (0.01 M in methanol) or PAMAM den-
drimers methanolic solutions were transferred to 5 mL flasks and the methanol was
evaporated under nitrogen stream. Then, solid Phenazine was added to ensure the
obtaining of a saturated solution. The samples were diluted to the appropriateon.2019.e01528
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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vigorously stirred for 2 hours. The samples were stored at room temperature in dark-
ness overnight. The next day the samples were shaken again for 2 hours and stored at
room temperature in absence of light for 48 hs. Finally, the solutions were sonicated
for 10 minutes and shaken for 2 hours. The unsolubilized Phenazine was removed
via filtration through a 0.45 mm Millipore membrane. The same procedure was
also carried out with Phenazine solutions in dendrimer absence. The samples of
guest-host Phenazine/dendrimer conjugates were studied by UV-visible light ab-
sorption (Shimadzu UV 2401 PC spectrophotometer) and 1H Nuclear Magnetic
Resonance spectroscopies (Bruker 400 MHz Advance II NMR spectrometer). In
the case of the analysis of the electronic transitions the same were observed for
the composite solutions in both, water and PBS medium, in the range of 420 and
700 nm, where the Phenazine compound exhibit light absorption in the two states,
neutral and as phenolate anion. Aqueous solutions of Phenazine-PAMAM and
Phenazine-PPI dendrimers composites were lyophilized and the solids were resolu-
bilized in D2O for NMR analysis. Phenazine-dendrimer formulation stability in wa-
ter was evaluated. Samples of the solutions were maintained at both, room
temperature and 4 C and analyzed periodically by UV-vis spectroscopy for two
months. In addition, the possible occurrence of precipitate, turbidity, crystallization
and color change were controlled by periodic eye observation and by UV-visible
light absorption spectroscopy. As control, the stability of a saturated Phenazine so-
lution in water in the absence of dendrimer was also tested using the same
methodology.2.3. Cells and cells culture
In order to analyze Phenazine-dendrimer systems biocompatibility, MDCK (derived
from canine kidney) cell lines were used. Cells were cultured in Dulbecco’s Modi-
fied Eagle Culture Medium (DMEM) (Gibco) supplemented with fetal bovine
serum 10% (Natocor) and antibiotic-antimycotic (Gibco) at 37 C, in a humidity
saturated atmosphere of 95% air e CO2 5%. For experiments, cells were plated in 96
wells (Biofil) at a density of 5000 cells/well in complete media for 24 h and treated
with phenazin 2  105 M in PBS, dendrimers (0.5  105 M, 1.25  105 M and
1.5 105 M PAMAM-AT (G¼ 3), 1.25 105 M PAMAM-AT (G¼ 1) and 1
105 M PPI (G¼ 4)) and Phenazine-dendrimer complexes (0.5 105 M PAMAM-
AT (G¼ 3)þ 1.8 104 M Phenazine, 1.25 105 M PAMAM-AT (G¼ 3)þ 3.8
 104 M Phenazine, 1.5  105 M PAMAM-AT (G ¼ 3) þ 5  104 M Phena-
zine, 1.25  105 M PAMAM-AT (G ¼ 1) þ 1.27  104 M Phenazine, 1  105
M PPI (G ¼ 4) þ 1.6  104 M Phenazine). The dendrimers and Phenazine/den-
drimers concentrations were choose according to the studies reported by Malik
et al [48] that showed that at very low dendrimers concentration there is not notice-
able effects on cells viability, and at higher concentrations the cytotoxic effect ison.2019.e01528
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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viability controls (cells cultured in complete DMEM), were run in six times.2.4. Cytotoxicity assays
Adherent cell viability was evaluated as described previously by Rivero et al. [49]
MTT technique measures 3- (4,5-dimethylthiazol-2 -yl) -2,5-diphenyltetrazolium
bromide (MTT) conversion to an insoluble formazan salt. The formazan is solubi-
lized in dimethyl sulfoxide (DMSO) and its absorbance, which is proportional to
adherent cell number was measured at 540 nm wavelength. Briefly, after 24 h of
treatment the media were removed and cells were incubated with MTT reagent (5
mg/mL in media) during 3 h. The reaction mixture was removed and formazan
precipitated were dissolved with 100 ml DMSO then, OD (540 nm) was registered.
Data were evaluated by one-way analysis of variance and Bonferroni post-hoc test
using Infostat software 2017 version (Universidad Nacional de Cordoba (FCA-
UNC), Cordoba, Argentina). Differences were considered significant at p value
less than 0.05.3. Results and discussion
3.1. Phenazine solubilization mediated by PAMAM and PPI
dendrimers in water
As was already mentioned, Phenazine has been shown to be a selective cyto-
toxic agent under hypoxic conditions and, in addition, has anti Trypanosoma
cruzi activity [36]. However, its water solubility is low for successful use
in vivo, reducing its bioavailability and effectiveness. The association of
this type of compounds with PAMAM and PPI dendrimers could increase
their aqueous solubility. Therefore, the ability of PAMAM-AT (G ¼ 1),
PAMAM-AT (G ¼ 3), PAMAM-OHT (G ¼ 3) and PPI (G ¼ 4) dendrimers
to be associated with Phenazine was evaluated in order to select the most suit-
able dendrimer for to act as molecular vehicle.
In Fig. 3, the UV-vis absorption spectra of Phenazine in aqueous solutions of the
studied PAMAM dendrimers are shown. In the figure it is also included the spectrum
obtained for a saturated solution of the drug in pure water, corresponding to its
maximum aqueous solubility (water solubility (Sw) ¼ 2  104 M). As can be
seen in Fig. 3, in dendrimers solutions the light absorption due to Phenazine mark-
edly increases with respect to the observed in pure water saturated solution, indi-
cating a significant enhancement in drug solubility. However, in the presence of
PAMAM-AT (G ¼ 1) and (G ¼ 3) amino terminal dendrimers, the Phenazine spec-
trum shows a bell-shaped band with wavelength maxima at lmax ¼ 560 nm. This
band is in agreement with the presence of Phenazine predominately as Phenolateon.2019.e01528
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 3. UV-vis absorption spectra of Phenazine in aqueous solution of PAMAM-AT (G ¼ 3) (a), PPI (G
¼ 4) (b), PAMAM-OHT (G ¼ 3) (c) and PAMAM-AT (G ¼ 1) (d). Dendrimer concentration: 1  104
M. The spectrum of a saturated Phenazine solution in pure water is also shown (e).
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(G ¼ 3) dendrimer aqueous solution, the Phenazine spectrum is different, exhibiting
an enhancement at short wavelength, which is in agreement with the presence of
Phenazine molecules in his neutral state in a higher proportion (Fig. A1). These facts
are due to the different pH of the dendrimer aqueous solutions. In the case of amine
terminated dendrimers the pH at the used concentration are 9.0 for PAMAM G1, 9.1
for PMAMA-G3 and 8.0 for PPI G4 dendrimer. As the Phenazine pKa is 5.6 (see
Fig. A2 in Additional Information), in PAMAM-AT solutions Phenazine predomi-
nates as Phenolate anion. On the other hand, the pH of PAMAM-OHT (G ¼ 3)
aqueous solution is 7.5, increasing the presence of neutral Phenazine in the
protonation-deprotonation equilibrium.
Although the dendrimer concentration is the same in all cases, the solubility incre-
ment of the drug is noticeably different. In solution of PAMAM-AT (G ¼ 3) 1 
104 M, an enhancement of 15-folds in the solubility of Phenazine with respect to
its solubility in water was achieved, whereas when using the PAMAM-OHT (G
¼ 3) dendrimer in the same concentration the solubility was increased 5 times. These
two dendrimers have the same size and number of terminal groups; however, they
differ in the terminal group type, PAMAM-AT possesses 32 amine terminal groups,
whereas in PAMAM-OHT there is the same number of hydroxyl groups. On the
other hand, the PAMAM-AT (G ¼ 1) that holds only 8 amine terminal groups in-
crease the Phenazine solubility 4 times at the same dendrimer concentration.on.2019.e01528
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 1. Characteristic
Phenazine (Dendrimer c
Dendrimer
PAMAM AT (G ¼ 1)
PAMAM AT (G ¼ 3)
PAMAM OHT (G ¼ 3)
PPI (G ¼ 4)
a Sw (Phenazine water solubili
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terminal groups in the PAMAM dendrimer, and its generation (Table 1).
The active compound solubility enhancement in aqueous solutions of PA-
MAM dendrimers can be attributed to different mechanisms of interaction be-
tween the dendrimer and the guest [50]. The existence of relatively nonpolar
cavities within the dendrimeric structure gives them the ability to encapsulate
molecules through hydrophobic interactions [24, 51, 52]. On the other hand,
the tertiary amine and amide groups in the dendrimers nanocavity can interact
with guests molecules by hydrogen-bond formation [24, 53]. In addition, if
the dendrimer has charged terminal groups, as is the case of PAMAM-AT,
it can be associated with charged drug molecules through electrostatic interac-
tions [24, 54, 55, 56]. In the aqueous solutions of the PAMAM-AT (G ¼ 1
and G ¼ 3) and PAMAM-OHT (G ¼ 3) dendrimers, Phenazine is mainly
found in anionic form. Thus, in the solutions of the amine terminal den-
drimers the drug can be associated through electrostatic interactions with
the cationic peripheral groups of the macromolecule. On the contrary, in
the case of the PAMAM-OHT dendrimer this type of interaction is not
possible, but the drug could be associated through hydrophobic interaction
and hydrogen-bonds in the nanocavities, as well as through hydrogen-bond
with the hydroxyl terminal groups [44].
Several studies demonstrate that the electrostatic interaction between ionized drugs
and dendrimeric charged end-groups is often more important than other types of in-
teractions, such as hydrophobic encapsulation or hydrogen-bond interactions [24,
25] Accordingly, in the present case, while PAMAM-AT (G ¼ 3) and PAMAM-
OHT (G ¼ 3) have the same size and interior, the lack of positively charged surface
groups in PAMAM-OHT (G ¼ 3) limits the Phenazine solubility enhancement. In
turn, although both PAMAM-AT (G¼ 3) and PAMAM-AT (G¼ 1) have positively
charged surface groups capable of being associated with Phenazine through electro-
static interactions, the former holds a higher number of cationic terminal groups,
which is reflected in a greater increase of Phenazine water solubility.s of the PAMAM and PPI dendrimers and increment in water solubility of
oncentration: 1  104 M).
Terminal group Surface charge Molecular
weight (g/mol)
Phenazine Solubility
enhancement
8 NH2 Cationic 1430 4 Sw
a
32 NH2 Cationic 6909 15 Sw
a
32 OH Neutral 6941 5 Sw
a
32 NH2 Cationic 3513 9 Sw
a
ty) ¼ 2  104 M.
on.2019.e01528
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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the PAMAM dendrimers. It can be seen that increasing the concentration of the den-
drimers, the amount of solubilized Phenazine growths. In the case of PAMAM-AT
(G ¼ 3) dendrimer the enhancement of drug solubility is more noticeable. As previ-
ously mentioned, for the same dendrimer concentration, PAMAM-AT (G ¼ 3) is
able to increase the Phenazine solubility more than PAMAM-AT (G ¼ 1) since
the (G¼ 3) dendrimer has more surface groups than that of (G¼ 1) (32 and 8 groups
respectively) and therefore more opportunities for electrostatic interaction with the
negatively charged drug molecules. Nevertheless, if the comparison is made for
the same concentration of terminal amino groups, it is found that both dendrimers
hold a similar capacity for increasing the drug solubility in water (Fig. 4(b)), indi-
cating that the amine terminal groups are directly involved in the solubility enhance-
ment effect.
However, it has been showed that the increment in dendrimer generation produces
congestion of terminal amino groups on the surface [25, 57], increasing the stericFig. 4. Aqueous solubility of Phenazine in the presence of increasing concentrations of PAMAM-AT
(G ¼ 1), PAMAM-AT (G ¼ 3) and PAMAM OHT (G ¼ 3) dendrimers (a) and as a function of the
concentration of terminal amino groups of the dendrimers PAMAM-AT (G ¼ 1) and PAMAM-AT
(G ¼ 3) (b).
on.2019.e01528
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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tive ability for drug solubility improvement. This is not the case in the present study,
at least until generation G ¼ 3. In this sense, like PAMAM-AT (G ¼ 3) dendrimer,
PPI (G ¼ 4) has 32 primary amine groups on its surface that could potentially
interact with Phenazine through electrostatic interactions. However, the interior of
the PPI dendrimer is more hydrophobic than that of PAMAM [58] having in conse-
quence greater ability for association with hydrophobic compounds in the inner den-
drimer nanocavities. Nevertheless, contrary to expectations, PPI (G ¼ 4) increases
the Phenazine solubility with less efficiency than PAMAM-AT with the same num-
ber of amine peripheral groups (Table 1). Therefore, the different Phenazine solubi-
lization capabilities of the PAMAM and PPI dendrimers cannot be attributed to a
difference in the number of surface charges or to the medium pH (pKa of amine ter-
minal groups are 9.75 for PPI [59] and 10.5 for PAMAM [60]). However, the
branching units of PPI dendrimers are shorter than those of PAMAM dendrimers
(4 versus 7 bonds), so PPI (G ¼ 4) is smaller than PAMAM-AT (G ¼ 3) (PPI diam-
eter ¼ 2.3 nm [61] versus PAMAM diameter ¼ 3.0 nm [62]). Therefore, in the PPI
dendrimer, the density of surface groups is higher; and could drive to a greater steric
hindrance in the binding of Phenazine molecules, affecting the efficiency of the drug-
dendrimer association for solubility enhancement. Also, this result is consequent
with the hypothesis that the surface ionic interactions contribute much more to the
drug solubility improvement than the encapsulation in the nanocavities through hy-
drophobic and hydrogen-bond interactions [24].3.2. Analysis of the association of phenazine with PAMAM and
PPI dendrimers by 1H-NMR spectroscopy
The association of Phenazine with dendrimers in water was studied by 1H-NMR
spectroscopy. NMR techniques are very useful tools for characterizing dendrimer-
guest complexes, as they provide information on the intermolecular interactions pre-
sent in the system [63].
The PAMAM-AT and PAMAM-OHT dendrimers have six types of protons signals
(Fig. 5a and b): four corresponding to the inner methylenes (groups a, b, c, d) and
two corresponding to the methylene groups of the outermost layer of the dendrimer,
close to the terminal groups (b’y d’ in Fig. 5) [64, 65]. In the 1H-NMR spectra of
these dendrimers, the peak for protons in d’ generally overlaps with protons in d,
whereas protons in b’ methylene groups overlaps with that in c [42]. In the 1H-
NMR spectra of PAMAM-AT in the absence and presence of Phenazine, dendrimer
proton signals appear in the zone of aliphatic hydrogens, between 2 and 4 ppm
(Fig. 5c). In presence of Phenazine, a significant downfield shift of the signals of
the methylene protons located in the outermost layer of the dendrimer (Hb0 y Hd0)
is observed. This indicates that the association occurs on the surface of theon.2019.e01528
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 5. Hydrogen atom labeling in the chemical structure of PAMAM-AT (G ¼ 1) (a) and PAMAM-
OHT (G ¼ 3) (b) dendrimer. Expanded region of the 1H NMR spectra of PAMAM-AT (G ¼ 1) (c)
and PAMAM-OHT (G ¼ 3) (d) in absence and in presence of Phenazine, in D2O.
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the Phenazine phenolic group [23, 25, 42, 66]. Furthermore, previous studies
showed that the guest encapsulation inside of the dendrimers shift the signals of in-
ternal protons to high field [25]. In the case of the Phenazine-PAMAM-AT system,
no signal upfield shift of the internal proton is observed in the presence of the drug.
Therefore, as has been demonstrated in previous studies [24], terminal amino groups
are the predominant factor in the solubilization enhancement of the anionic drug by
the cationic dendrimers.
Moreover, in the case of PPI dendrimers, the association with Phenazine produces a
downfield shift of the NMR signals attributed to the aliphatic protons located in im-
mediate vicinity of the terminal amino groups (see the NMR spectra, Fig. A3, in
Additional Information) [67]. This fact is in fully agreement with our hypothesis
that the guest-host association occurs by ionic interactions between the amines
located in the outermost layer of the PAMAM and PPI dendrimers and the Phenazine
phenolic group [31, 56].
On the other hand, when analyzing the 1H-NMR spectrum of the PAMAM-OHT
dendrimer in the absence and in the presence of Phenazine, in D2O, it can be seen
that the positions of the dendrimer signals practically do not change in the presence
of drug (Fig. 5d). This allows us to infer that Phenazine does not associate with theon.2019.e01528
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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hydrogen-bond interaction between the drug and the macromolecule. However, in
the UV-vis spectroscopy studies, an increase in the solubility of the drug in aqueous
PAMAM-OHT solution was observed with respect to the saturated Phenazine solu-
tion in pure water (Fig. 3). This increase in solubility can be attributed to the fact that
aqueous solutions of PAMAM-OHT dendrimer have a more basic pH than pure wa-
ter. Therefore, in the presence of the PAMAM-OHT dendrimer, Phenazine is more
ionized than in pure water; as the ionized drug is more soluble in water than when it
is in the neutral state, its solubility increases in the presence of the dendrimer. In the
case of PAMAM-AT dendrimers whose aqueous solutions are also more basic than
pure water, the increase in Phenazine solubility would also partly be due to an in-
crease in the pH of the solution. However, unlike for OHT dendrimer, in amino-
terminal dendrimers the solubility of the drug would also be due to the association
with the macromolecule, according to the evidence found by 1H-NMR spectroscopy.
To corroborate this hypothesis, the solubility of Phenazine in PBS and in solutions of
the PAMAM-AT and OHT dendrimers in PBS was analyzed.3.3. Phenazine solubilization mediated by PAMAM dendrimers
in PBS
Due to the fact that the presence of PAMAM dendrimers affect the water pH,
and that in aqueous solution, neutral Phenazine (phenolic form) and the corre-
sponding phenolate anion coexist in equilibrium, the drug-dendrimer association
was investigated in buffered media (PBS pH ¼ 7.4). At physiological pH Phen-
azine is mainly found as phenolate anion (pKa ¼ 5.6). Fig. 6 shows the UV-vis
absorption spectra of Phenazine in the presence of PAMAM-AT (G ¼ 3) and
PAMAM-OHT (G ¼ 3), in PBS. In addition, the spectrum of a saturated solu-
tion of the drug in PBS, corresponding to its maximum solubility in PBS, is
shown for comparison (PBS solubility (SPBS) ¼ 5  104 M). As can be clearly
see in Fig. 6, the Phenazine absorbance in PBS is almost the same with and
without PAMAM-OHT (G ¼ 3). Thus there is not solubility enhancement
due to the presence of OHT terminal dendrimer, and the effect observed in
pure water was due to the changes in the media pH. This show that there is
not specific interaction between PAMAM-OHT (G ¼ 3) dendrimer and Phena-
zine, in agreement with the H1NMR studies.
On the other hand, in PAMAM-AT (G ¼ 3) dendrimer solution the absor-
bance of Phenazine increases relative to the saturated drug solution in PBS,
indicating that the drug solubility is remarkably enhanced (Fig. 6). At pH
¼ 7.4 both, the terminal amino groups of the dendrimer [68] and the phenol
group of the drug are ionized. Therefore, the increase in Phenazine solubility
can be attributed to the drug-dendrimer association through the ionicon.2019.e01528
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 6. UV-vis absorption spectra of Phenazine in presence of PAMAM-AT (G ¼ 3) (a), PPI (G ¼ 4) (b)
and PAMAM-OHT (G ¼ 3) (c) dendrimer in PBS. Dendrimer concentration: 1  104 M. The spectrum
of a saturated Phenazine solution in PBS is also shown (d).
Fig. 7. Schematic illustration of Phenazine in presence of PAMAM-AT and PAMAM-OHT dendrimer
in PBS. (a) Proposed ionic interaction between cationic PAMAM dendrimer and deprotonated Phenazine
molecules. (b) Phenazine does not associate with PAMAM-OHT dendrimer.
13 https://doi.org/10.1016/j.heliyon.2019.e01528
2405-8440/ 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Article Nowe01528
14 https://doi.org/10.1016/j.heliy
2405-8440/ 2019 Published
(http://creativecommons.org/li
Article Nowe01528interactions between the terminal groups of the dendrimer and the phenolate
group of the therapeutic compound (Fig. 7), in agreement with NMR shift
observed in the protons that belongs to the peripheral groups in PAMAM-
AT dendrimer when Phenazine is present in the aqueous media.
Regarding PPI dendrimer, the Phenazine solubility increase as compared with pure
PBS media, but this enhancement is low in comparison with the same effect obtained
with PAMAM-AT (G¼ 3) dendrimer, in agreement with the results obtained in pure
water, that was attributed to the steric hindrance produced in PPI- Phenazine
association.3.4. Stability of the phenazine-dendrimer complexes
In order to evaluate the stability of Phenazine-dendrimer associations, solu-
tions of the complexes maintained at 4 C in refrigerator and at room temper-
ature were analyzed periodically. Possible precipitation, turbidity,
crystallization, spectral changes and drug release were monitored. The stabil-
ity of Phenazine in the absence and presence of the dendrimers in water at
room temperature over time is shown in Fig. 8. It can be seen that there
were no significant changes in the remaining percentage of Phenazine in so-
lution as a function of time, whether the drug is in pure water or in aqueous
solution of the PAMAM-AT (G ¼ 1), PAMAM-AT (G ¼ 3) or PPI (G ¼ 4)
dendrimers, indicating that drug-dendrimer associations are stable over time.
Similar results were obtained for water solutions at 4 C and for drug-
dendrimer association in PBS media at both temperatures. This is very impor-
tant considering that the study of such systems aims at the preparation of for-
mulations for future clinical application.Fig. 8. Stability of Phenazine in absence and presence of the PAMAM and PPI dendrimers in water for
two months. Dendrimer concentration: 1.0  104 M.
on.2019.e01528
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Phenazine-dendrimer systems are investigated for their potential application in
the development of new treatment for clinical use. In this way, the biocom-
patibility analysis of the Phenazine-dendrimer complexes was initiated through
cytotoxicity assays. The cytotoxic effects of Phenazine, PAMAM-AT (G ¼ 1),
PAMAM-AT (G ¼ 3) and PPI (G ¼ 4) dendrimers and their corresponding
complexes with the active compound were determined in normal MDCK cells
by MTT assays as detailed in section 2.4. The percentages of cell viability
obtained in each case are shown, as optical density (540 nm) in Fig. 9.
The MDCK viability data showed that a single treatment of Phenazine and
dendrimers did not produce cytotoxic effect, with the exception of treatment
with PPI (G ¼ 4). For cationic dendrimers, such as PAMAM-AT and PPI,
the surface charge is known to be the predominant factor in polymer cytotox-
icity. Both PAMAM-AT (G ¼ 3) and PPI (G ¼ 4) has 32 surface primary
amine groups, so it would be expected that both dendrimers have similar
cytotoxicity effect [25]. However, the PPI dendrimer (G ¼ 4) has a more lipo-
philic areas than PAMAM-AT, being suitable to traversing the lipophilic re-
gion of cell membrane [50]. Thus, PPI dendrimer (G ¼ 4) have a greater
ability to perturb the cell membrane stability than the PAMAM-AT den-
drimer, showing cytotoxicity. However, the Phenazine anionic drug associa-
tion with PPI reduce the cytotoxic effects of the polycationic carrier
(Fig. 9) by masking the surface charge [52].Fig. 9. MDCK cells viability treated with Phenazine (Phe), PAMAM-AT (G ¼ 1), PAMAMAT (G ¼ 3),
PPI (G ¼ 4) and their combination during 24 hs. Phenazine saturated solution. Dendrimer Concentration
1.0 104 M (highest studied concentration). Data represented media of absorbance  Standard Error (n
¼ 6) (p  0.05).
on.2019.e01528
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The use of amine terminal dendrimers such PAMAM-AT and PPI allows the genera-
tion of formulations that increase the water solubility of 7-bromo-2-hydroxy-phenazine
N5,N10-dioxide, a compound that exhibited in vitro antitumoral activity whit high selec-
tivity for hypoxia conditions and anti-trypanosomal activity against Trypanosoma
cruzi, but whose low solubility in physiological media decreases its bioavailability
and effectiveness for successful in vivo usage. NMR studies showed that the amino
groups in dendrimeric periphery are essential in the solubilization enhancement. This
process is originated in the association of Phenazine phenolic group trough ionic inter-
actions with the dendrimers amino terminal residues. In fact, the PAMAM-AT (G¼ 3)
dendrimer with 32 amine terminal groups generates the higher solubility increment in
water and PBS media. The formulation is stable in time and exhibit no cytotoxic effects
for normal MDCK cells, making the drug-carried association a suitable strategy for the
generation of a drug delivery system for phenazine derivatives.Declarations
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